Celsion Co. (NASDAQ:CLSN – Get Rating) saw a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 95,400 shares, a drop of 15.0% from the June 30th total of 112,200 shares. Approximately 1.4% of the shares of the company are sold short. Based on an average daily trading volume, of 61,600 shares, the days-to-cover ratio is presently 1.5 days.
Celsion Price Performance
NASDAQ:CLSN opened at $2.18 on Wednesday. Celsion has a 52 week low of $1.80 and a 52 week high of $17.70. The firm’s 50-day simple moving average is $2.11 and its 200 day simple moving average is $3.79. The company has a quick ratio of 6.60, a current ratio of 6.60 and a debt-to-equity ratio of 0.13.
Celsion (NASDAQ:CLSN – Get Rating) last released its quarterly earnings results on Monday, May 16th. The biotechnology company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.81). Celsion had a negative return on equity of 45.34% and a negative net margin of 5,110.80%. The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.11 million. During the same period in the prior year, the business posted ($1.35) earnings per share. On average, analysts forecast that Celsion will post -5.08 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Hedge Funds Weigh In On Celsion
A hedge fund recently raised its stake in Celsion stock. GSA Capital Partners LLP raised its position in Celsion Co. (NASDAQ:CLSN – Get Rating) by 435.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 133,006 shares of the biotechnology company’s stock after buying an additional 108,155 shares during the quarter. GSA Capital Partners LLP owned about 0.15% of Celsion worth $72,000 at the end of the most recent quarter.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
- Get a free copy of the StockNews.com research report on Celsion (CLSN)
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.